Elevated Interleukin-12 Is A Plasma Marker Of Poor Prognosis In Stage III Melanoma Patients
Apr 17th 2008Drug InformationCancer
New research has established that elevated blood levels of interleukin-12, which rise as we age, independently predicts poor prognosis in patients with melanoma. Interleukin-12 is a biological therapeutic agent that has been shown to act on the immune system and increase the body’s ability to fight disease.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
